Cohance Lifesciences Limited — Important, 15-12-2025: Updates

Cohance Lifesciences reported Q2 consolidated revenue down 8% YoY to ₹555.6 Cr and H1 up 1.2% to ₹1,104.9 Cr. Results were impacted by destocking and biotech funding delays, particularly at NJ Bio. Gross margins improved. A US FDA approval for an innovator drug marks a key win. The company anticipates a stronger 2H, targeting ₹8,500 Cr revenue by 2030.